ポンペ病の世界市場レポート 2025年

ポンペ病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で23億2,000万米ドルに成長します。予測期間の成長は、継続的な研究開発、新生児スクリーニングプログラムの拡大、遺伝子治療の進歩、希少疾患に対する世界の投資の増加、患者中心の医薬品開発、臨床試験や研究イニシアチブの拡大、個別化医療アプローチの市場重視などに起因すると考えられます。予測期間における主な動向としては、製品革新、技術進歩、患者支援プログラムの実施、患者管理における遠隔医療の採用拡大、アクセス拡大プログラムのための提携などが挙げられます。

ポンペ病の有病率の上昇がポンペ病市場の成長を促進すると予測されます。グリコーゲン貯蔵病II型または酸性マルターゼ欠乏症としても知られるこの稀な遺伝性疾患は、複雑な糖分子であるグリコーゲンが様々な身体組織、特に筋肉や臓器に蓄積することが特徴です。ポンペ病の治療には、蛋白補充療法、アルグルコシダーゼ・アルファ、ネクスビアザイム点滴静注などがあります。2022年6月にEuropean Medicines Agency Highlightsが報告したようなポンペ病症例の増加は、ポンペ病市場の拡大に寄与すると予想されます。欧州だけでも、ポンペ病を引き起こす可能性のある変異を持つ幼児発症者が約224人、若年発症者が471人、成人発症者が20,490人います。

ヘルスケア支出の増加は、今後のポンペ病市場の成長を促進する上で重要な役割を果たしています。政府や保険業者は、革新的な治療法へのアクセスを確保することの重要性を徐々に認識しつつあります。例えば、2023年5月、英国の政府機関である国家統計局の報告書によると、英国のヘルスケア支出は2022年から2023年にかけて5.6％増加したのに対し、2022年の伸びはわずか0.9％であったことが明らかになった。2023年の英国のヘルスケア支出は約3,176億3,000万米ドル（2,920億英ポンド）。このように、医療費の増加はポンペ病市場を前進させると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ポンペ病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のポンペ病市場：成長率分析
• 世界のポンペ病市場の実績：規模と成長, 2019-2024
• 世界のポンペ病市場の予測：規模と成長, 2024-2029, 2034F
• 世界ポンペ病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のポンペ病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 典型的な幼児型
• 非典型的乳児型
• 後発型
• その他のタイプ
• 世界のポンペ病市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 遺伝子検査
• 出生前検査
• その他の診断
• 世界のポンペ病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のポンペ病市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法（ERT）
• 基質還元療法（SRT）
• 遺伝子治療、その他の治療
• 世界のポンペ病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院または診療所
• 医薬品
• 研究者
• その他のエンドユーザー
• 世界のポンペ病市場、古典的乳児型のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期発症の古典ポンペ病
• シビアクラシックポンペ病
• 世界のポンペ病市場、非典型的乳児型のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度非典型的乳児ポンペ病
• 非典型的乳児型の変異
• 世界のポンペ病市場、遅発型のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人発症ポンペ病
• 若年発症ポンペ病
• 世界のポンペ病市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 無症状感染者
• ポンペ病のその他の珍しいバリエーション

第7章 地域別・国別分析

• 世界のポンペ病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のポンペ病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ポンペ病市場：競合情勢
• ポンペ病市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Amicus Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sangamo BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Asklepios BioPharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Audentes Therapeutics Inc.
• Genethon
• Maze Therapeutics Inc.
• Avidity Biosciences Inc.
• EpiVax Inc.
• M6P Therapeutics
• Oxyrane UK Limited
• Valerion Therapeutics LLC
• Abeona Therapeutics Inc.
• BioMarin Pharmaceutical
• Genzyme Corporation
• Novartis AG
• Ultragenyx Pharmaceutical
• Aro Biotherapeutics Company
• Akashi Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ポンペ病市場2029：新たな機会を提供する国
• ポンペ病市場2029：新たな機会を提供するセグメント
• ポンペ病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pompe disease is a genetic disorder characterized by the accumulation of a complex sugar known as glycogen within the cells of the body. This condition arises due to a deficiency in the enzyme acid alfa glucosidase (GAA), responsible for breaking down complex carbohydrates in the body.

Pompe disease manifests in several forms, including the classic infantile form, non-classic infantile form, late-onset form, and others. The classic infantile form is the most widely recognized, presenting significant heart dysfunction and noticeable hypotonia within a few months of birth. Diagnosis involves various methods such as blood tests, genetic tests, prenatal tests, and others. Treatment options for Pompe disease encompass oral, parenteral, and alternative approaches. Therapies include enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and other modalities utilized by hospitals, clinics, pharmaceuticals, researchers, and other stakeholders.

The pompe disease market research report is one of a series of new reports from The Business Research Company that provides pompe disease market statistics, including pompe disease industry global market size, regional shares, competitors with a pompe disease market share, detailed pompe disease market segments, market trends and opportunities, and any further data you may need to thrive in the pompe disease industry. This pompe disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pompe disease market size has grown steadily in recent years. It will grow from $1.74 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to increased awareness and diagnosis, orphan drug designation and incentives, global collaborations and research initiatives, patient advocacy, and support groups

The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to continued research and development, expansion of newborn screening programs, advancements in gene therapy, increasing global investment in rare diseases, patient-centric drug development, expansion of clinical trials and research initiatives, market emphasis on personalized medicine approaches. Major trends in the forecast period include product innovation, technological advancements, implementation of patient support programs, growing adoption of telemedicine for patient management, and collaborations for expanded access programs.

The rising prevalence of Pompe disease is anticipated to drive the growth of the Pompe disease market. Also known as glycogen storage disease type II or acid maltase deficiency, this rare genetic disorder is characterized by the accumulation of glycogen, a complex sugar molecule, in various body tissues, particularly in muscles and organs. Treatments for Pompe disease include protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. The increase in Pompe disease cases, such as those reported by the European Medicines Agency Highlights in June 2022, is expected to contribute to the expansion of the Pompe disease market. In Europe alone, there are approximately 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset individuals with mutations potentially causing Pompe disease.

The increasing healthcare expenditure is playing a significant role in driving the growth of the Pompe disease market in the future. Governments and insurance providers are progressively acknowledging the importance of ensuring access to innovative therapies. For example, in May 2023, a report from the Office for National Statistics, a UK government department, revealed that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth of just 0.9% in 2022. In 2023, the UK's healthcare expenditure was approximately $317.63 billion (£292 billion). Thus, the rising healthcare expenditure is expected to propel the Pompe disease market forward.

Product innovations are a prominent trend in the Pompe disease market, with major companies adopting innovations to maintain their market position. For example, in September 2023, Amicus Therapeutics received approval from the U.S. Food and Drug Administration (FDA) for Pombiliti and Opfolda, a two-component therapy designed for adults with late-onset Pompe disease. The therapy combines a recombinant human GAA enzyme (rhGAA) for increased uptake into muscle cells with an enzyme stabilizer (Opfolda) to stabilize the enzyme in the blood. This FDA approval highlights the importance of advancements in science and medicine.

Major companies in the Pompe disease market are prioritizing strategic partnerships to enhance product development, broaden market reach, and improve solutions for animal health. A strategic partnership generally refers to a collaborative relationship between two or more organizations that combine their resources, expertise, and efforts to achieve shared goals or objectives. For example, in June 2024, Shionogi & Company, Limited, a Japanese pharmaceutical firm, entered into a global licensing agreement with Maze Therapeutics, a US-based biotechnology company, for MZE001, an investigational oral medication aimed at treating Pompe disease. Under this agreement, Shionogi secures exclusive rights to MZE001 and its associated intellectual property, which includes an initial payment of $150 million, along with potential milestone and royalty payments. This agreement was finalized following the necessary 30-day review period mandated by U.S. antitrust law (HSR Act).

In January 2022, Hansa Biopharma AB and Asklepios BioPharmaceutical Inc. collaborated to assess the potential use of imlifidase as a pre-treatment before administering AskBio's gene therapy for Pompe disease. This partnership involves a pre-clinical and clinical feasibility program for patients with pre-existing neutralizing antibodies to adeno-associated virus (AAV). Hansa will receive a $5 million payment, and AskBio holds an exclusive option for a full development and commercialization agreement based on the results of an initial Phase I/II study. AskBio will lead the pre-clinical and clinical studies, while Hansa will provide materials and additional support outlined in the feasibility program.

Major companies operating in the pompe disease market include F. Hoffmann-La Roche AG, Sanofi S.A., Amicus Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC, Abeona Therapeutics Inc., BioMarin Pharmaceutical, Genzyme Corporation, Novartis AG, Ultragenyx Pharmaceutical, Aro Biotherapeutics Company, Akashi Therapeutics, Protalix BioTherapeutics, AVROBIO Inc., Catabasis Pharmaceuticals

North America was the largest region in the pompe disease market in 2024. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pompe disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pompe disease market includes revenues earned by entities by lumizyme, alglucosidase alfa, nexviazyme, and aval glucosidase alfa. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pompe Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pompe disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pompe disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pompe disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types
• 2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis
• 3) By Route Of Administration: Oral, Parenteral, Other routes Of administrations
• 4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies
• 5) By End Users: Hospitals Or Clinics, Pharmaceuticals, Researchers, Other End-Users
• Subsegments:
• 1) By Classic Infantile Form: Early-Onset Classic Pompe Disease; Severe Classic Pompe Disease
• 2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease; Variants of Non-Classic Infantile Form
• 3) By Late-Onset Form: Adult-Onset Pompe Disease; Juvenile-Onset Pompe Disease
• 4) By Other Types: Asymptomatic Carriers; Other Rare Variants of Pompe Disease
• Companies Mentioned: F. Hoffmann-La Roche AG; Sanofi S.A.; Amicus Therapeutics Inc.; Sangamo BioSciences Inc.; Asklepios BioPharmaceutical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pompe Disease Market Characteristics

3. Pompe Disease Market Trends And Strategies

4. Pompe Disease Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pompe Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pompe Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pompe Disease Market Growth Rate Analysis
• 5.4. Global Pompe Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pompe Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pompe Disease Total Addressable Market (TAM)

6. Pompe Disease Market Segmentation

• 6.1. Global Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Infantile Form
• Non-Classic Infantile Form
• Late-Onset Form
• Other Types
• 6.2. Global Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Test
• Genetic Test
• Prenatal Test
• Other Diagnosis
• 6.3. Global Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other routes Of administrations
• 6.4. Global Pompe Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Gene Therapy, Other Therapies
• 6.5. Global Pompe Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Or Clinics
• Pharmaceuticals
• Researchers
• Other End-Users
• 6.6. Global Pompe Disease Market, Sub-Segmentation Of Classic Infantile Form, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset Classic Pompe Disease
• Severe Classic Pompe Disease
• 6.7. Global Pompe Disease Market, Sub-Segmentation Of Non-Classic Infantile Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Non-Classic Infantile Pompe Disease
• Variants of Non-Classic Infantile Form
• 6.8. Global Pompe Disease Market, Sub-Segmentation Of Late-Onset Form, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult-Onset Pompe Disease
• Juvenile-Onset Pompe Disease
• 6.9. Global Pompe Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asymptomatic Carriers
• Other Rare Variants of Pompe Disease

7. Pompe Disease Market Regional And Country Analysis

• 7.1. Global Pompe Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pompe Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pompe Disease Market

• 8.1. Asia-Pacific Pompe Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pompe Disease Market

• 9.1. China Pompe Disease Market Overview
• 9.2. China Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pompe Disease Market

• 10.1. India Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pompe Disease Market

• 11.1. Japan Pompe Disease Market Overview
• 11.2. Japan Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pompe Disease Market

• 12.1. Australia Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pompe Disease Market

• 13.1. Indonesia Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pompe Disease Market

• 14.1. South Korea Pompe Disease Market Overview
• 14.2. South Korea Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pompe Disease Market

• 15.1. Western Europe Pompe Disease Market Overview
• 15.2. Western Europe Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pompe Disease Market

• 16.1. UK Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pompe Disease Market

• 17.1. Germany Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pompe Disease Market

• 18.1. France Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pompe Disease Market

• 19.1. Italy Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pompe Disease Market

• 20.1. Spain Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pompe Disease Market

• 21.1. Eastern Europe Pompe Disease Market Overview
• 21.2. Eastern Europe Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pompe Disease Market

• 22.1. Russia Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pompe Disease Market

• 23.1. North America Pompe Disease Market Overview
• 23.2. North America Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pompe Disease Market

• 24.1. USA Pompe Disease Market Overview
• 24.2. USA Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pompe Disease Market

• 25.1. Canada Pompe Disease Market Overview
• 25.2. Canada Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pompe Disease Market

• 26.1. South America Pompe Disease Market Overview
• 26.2. South America Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pompe Disease Market

• 27.1. Brazil Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pompe Disease Market

• 28.1. Middle East Pompe Disease Market Overview
• 28.2. Middle East Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pompe Disease Market

• 29.1. Africa Pompe Disease Market Overview
• 29.2. Africa Pompe Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pompe Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pompe Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pompe Disease Market Competitive Landscape And Company Profiles

• 30.1. Pompe Disease Market Competitive Landscape
• 30.2. Pompe Disease Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amicus Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sangamo BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Asklepios BioPharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Pompe Disease Market Other Major And Innovative Companies

• 31.1. Audentes Therapeutics Inc.
• 31.2. Genethon
• 31.3. Maze Therapeutics Inc.
• 31.4. Avidity Biosciences Inc.
• 31.5. EpiVax Inc.
• 31.6. M6P Therapeutics
• 31.7. Oxyrane UK Limited
• 31.8. Valerion Therapeutics LLC
• 31.9. Abeona Therapeutics Inc.
• 31.10. BioMarin Pharmaceutical
• 31.11. Genzyme Corporation
• 31.12. Novartis AG
• 31.13. Ultragenyx Pharmaceutical
• 31.14. Aro Biotherapeutics Company
• 31.15. Akashi Therapeutics

32. Global Pompe Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pompe Disease Market

34. Recent Developments In The Pompe Disease Market

35. Pompe Disease Market High Potential Countries, Segments and Strategies

• 35.1 Pompe Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pompe Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pompe Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer